海尔生物(688139) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved total operating revenue of RMB 2.328 billion, a year-on-year increase of 2.0%[5] - Operating profit decreased by 33.72% to RMB 266.34 million, while total profit fell by 34.13% to RMB 264.76 million[3] - Net profit attributable to shareholders of the parent company was RMB 250.73 million, down 31.61% compared to the previous year[3] Revenue Breakdown - The company’s overseas revenue reached RMB 840 million, a 17.9% increase, accounting for 36% of total revenue, up 5 percentage points from 2024[5] - Domestic revenue declined by 5.5% to RMB 1.47 billion, but showed a recovery with a 14.5% increase in Q4[6] - New industries contributed 48.5% of total revenue, growing by 8.8%, while low-temperature storage revenue decreased by 3.9%[8] - AI-related revenue accounted for 15% of total revenue, an increase of 2.5 percentage points from 2024[9] Profitability and Margins - The company's gross profit margin was 46.8%, impacted by new capacity ramp-up, but improved by approximately 0.7 percentage points in Q4[9] Strategic Focus - The company is focusing on global market expansion and innovation, with new products launched including an automated tumor liquid robot and a high-speed centrifuge[10] Investment Risks - The company warns of investment risks as the financial data is preliminary and unaudited, with final figures to be disclosed in the annual report[13]